VivoSeq
Oncology

Stage III Colon Cancer

5

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Stage III Colon Cancer is an early-stage landscape with 5 programs across 3 companies. The most active players are Incyte, Roche, Hellenic Oncology Research Group.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

PreclinicalRoche logo

Roche

0 programs

PreclinicalH

Hellenic Oncology Research Group

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical5

Mfolfox6 3-6 Month

NRG Oncology

CAPOX 3 Month

NRG Oncology

Mfolfirinox

Incyte

Mfolfox6 6 Month

NRG Oncology

CAPOX 6 Month

NRG Oncology

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

24

clinical trials

Completed13 · 54%
Unknown status5 · 21%
Recruiting4 · 17%
Not yet recruiting1 · 4%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

24 trials

CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Recruiting·WWest China Hospital·Phase 2·NCT06242418·60 enrolled
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Recruiting·MMassachusetts General Hospital·Phase 3·NCT03803553·400 enrolled
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Recruiting·—·Phase 2/3·NCT05179889·308 enrolled
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Recruiting·NRG Oncology·Preclinical·NCT05174169·1,912 enrolled
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT07156682·21 enrolled
High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer
Completed·RRobert Roessle Klinik·Phase 3·NCT00004150
GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
Completed·UUniversity of Rochester·Phase 2·NCT00262808·50 enrolled
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
Completed·National Cancer Institute (NCI)·Phase 3·NCT00004931·2,472 enrolled
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
Completed·EEpimmune·Phase 1·NCT00054912·18 enrolled
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Completed·Roche logoRoche·Phase 3·NCT00112918·3,451 enrolled
Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer
Completed·JJules Bordet Institute·N/A·NCT00994864·235 enrolled
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Completed·National Cancer Institute (NCI)·Phase 3·NCT00096278·2,710 enrolled
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
Completed·UUNICANCER·Phase 3·NCT00005979
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Completed·National Cancer Institute (NCI)·Phase 3·NCT00003835·1,260 enrolled
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
Completed·Roche logoRoche·N/A·NCT01442155·74 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)